Korean stocks with litigation filings
Lawsuit filed or ruled on, disclosed in the past 180 days. Add more filters below to narrow the list.
Add filters earnings · returns · ownership · events · caution · market · industry · sort
13 Korean listed companies match this signal: lawsuit filed or ruled on, disclosed in the past 180 days. 4 are on KOSPI and 9 on KOSDAQ. Sorted by most news articles in the past 24 hours, the list starts with Namyang Dairy Products, KS Industry and LDT.
Litigation 13
| Company | Articles 24h | Latest quarter op. profit | Dividend yield | Signals |
|---|---|---|---|---|
| Namyang Dairy Products KOSPI · Food products | 21 | ₩1.3bn | 2.8% | Litigation |
| KS Industry KOSDAQ | 4 | −₩806m | – | Private placement Dilution risk 4 quarters of losses Insider selling Litigation |
| LDT KOSDAQ | 4 | ₩874m | – | Litigation |
| Mgen Solutions KOSDAQ | 2 | −₩2.9bn | – | 4 quarters of losses Litigation |
| Dong-Ah Geological Engineering Company KOSPI | 1 | ₩5.0bn +20% | – | Litigation |
| Mobile Appliance KOSDAQ | 0 | −₩2.8bn | – | Swung to loss 4 quarters of losses Litigation |
| Enzychem Lifesciences KOSDAQ | 0 | −₩4.1bn | – | Revenue +30% 4 quarters of losses Litigation |
| Daol Investment & Securities KOSPI | 0 | ₩17.1bn -13% | – | Revenue +30% Litigation |
| PonyLink KOSDAQ | 0 | −₩4.4bn | – | 4 quarters of losses Litigation |
| Cellfie Global KOSDAQ | 0 | −₩786m | – | Supply contract Litigation |
| RN2 Technologies KOSDAQ | 0 | −₩921m | – | 4 quarters of losses Litigation |
| Dongsung Pharmaceutical KOSPI | 0 | −₩2.0bn | – | Litigation |
| Logis Mon KONEX | 0 | – | – | Litigation |
Signals are generated automatically from DART filings (quarterly results, ownership reports, major-event reports and filing titles) and news counts. Prices and trading flows are not included. Not investment advice.
What this list means
Filings on lawsuits filed or ruled on. The claim size relative to equity and the counterparty indicate how significant a case may be.
Lists are generated automatically from filings and are not investment advice.